Cargando…

Proteomic profiles of prevalent mild cognitive impairment and Alzheimer's disease among adults with Down syndrome

INTRODUCTION: We sought to determine if a proteomic profile approach developed to detect Alzheimer's disease (AD) in the general population would apply to adults with Down syndrome (DS). METHODS: Plasma samples were obtained from 398 members of a community‐based cohort of adults with DS. A tota...

Descripción completa

Detalles Bibliográficos
Autores principales: Petersen, Melissa, Zhang, Fan, Krinsky‐McHale, Sharon J., Silverman, Wayne, Lee, Joseph H., Pang, Deborah, Hall, James, Schupf, Nicole, O'Bryant, Sid E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233426/
https://www.ncbi.nlm.nih.gov/pubmed/32435687
http://dx.doi.org/10.1002/dad2.12023
Descripción
Sumario:INTRODUCTION: We sought to determine if a proteomic profile approach developed to detect Alzheimer's disease (AD) in the general population would apply to adults with Down syndrome (DS). METHODS: Plasma samples were obtained from 398 members of a community‐based cohort of adults with DS. A total of n = 186 participants were determined to be non‐demented and without mild cognitive impairment (MCI) at baseline and throughout follow‐up; n = 50 had prevalent MCI; n = 42 had prevalent AD. RESULTS: The proteomic profile yielded an area under the curve (AUC) of 0.92, sensitivity (SN) = 0.80, and specificity (SP) = 0.98 detecting prevalent MCI. For detecting prevalent AD, the proteomic profile yielded an AUC of 0.89, SN = 0.81, and SP = 0.97. The overall profile closely resembled our previously published profile of AD in the general population. DISCUSSION: These data provide evidence of the applicability of our blood‐based algorithm for detecting MCI/AD among adults with DS.